Therapeutics Pipeline
Cervical Dystonia
In October 2020, Revance announced positive topline results from the pivotal ASPEN-1 Phase 3 clinical trial evaluating the efficacy of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia. The results support the potential use of DaxibotulinumtoxinA for Injection as a new treatment option for cervical dystonia, where duration is a significant unmet need.2,3
revance
Cervical Dystonia in Numbers
40-60 years of age
Women to Men
Women are twice as likely to be affected by cervical dystonia
Americans
An estimated 60,000 Americans suffer from cervical dystonia
Learn More About Cervical Dystonia with Dr. Joseph Jankovic video
* Not an actual patient
Unmet need
71% of patients desire longer lasting benefits between treatments2
Revance Announces Top-Line Results for ASPEN-1
ASPEN-1 is a Phase 3, randomized, double-blind, placebo-controlled, parallel group clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.
ASPEN-1 study results suggest that DaxibotulinumtoxinA for Injection has the potential to reduce frequency of cervical dystonia treatments by up to 50% annually.
The study met the primary endpoint demonstrating a statistically significant improvement in the averaged change in total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score at weeks 4 and 6 compared to placebo. TWSTRS was used to assess each patient’s severity, disability and pain caused by cervical dystonia.
Met the primary endpoint demonstrating a statistically significant improvement in the averaged change in TWSTRS-total score at weeks 4 and 6 compared to placebo.
Median Duration of Effect up to 24 weeks with 125U dose of DaxibotulinumtoxinA for Injection.
No unexpected adverse events were observed. The three most common treatment-related adverse events (for 125 Units and 250 Units) were injection site pain (7.9%, 4.7%), headache (4.7%, 4.7%), and injection site erythema (4.7%, 2.3%).
Other Common Adverse Events (for 125 Units and 250 Units) were Dysphagia (1.6%, 3.9%) and muscular weakness (4.7%, 2.3%).
DaxibotulinumtoxinA for Injection was approved by the FDA in [MM/YY] for the [insert based on label] and is currently being evaluated in additional therapeutic and aesthetic indications.
References
1 – Dystonia Medical Research Foundation. Retrieved from: https://dystonia-foundation.org/what-is-dystonia/types-dystonia/cervical-dystonia/. Accessed 8/11/20
2 – Comella, C., Ferreira, J.J., Pain, E. et al. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol (2020). https://doi.org/10.1007/s00415-020-10217-7
3 – Revance Market Research 2019: Understanding the Value of DaxibotulinumtoxinA for Injection’s Therapeutic Franchise
4 – NORD (National Organization for Rare Disorders). Cervical Dystonia (July 19, 2019) Retrieved from: https://rarediseases.org/rare-diseases/cervical-dystonia/. Accessed 9/29/20
5 – Marsh W, et al. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurology 2014
References
1 – Dystonia Medical Research Foundation. Retrieved from: https://dystonia-foundation.org/what-is-dystonia/types-dystonia/cervical-dystonia/. Accessed 8/11/20
2 – Comella, C., Ferreira, J.J., Pain, E. et al. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol (2020). https://doi.org/10.1007/s00415-020-10217-7
3 – Revance Market Research 2019: Understanding the Value of DaxibotulinumtoxinA for Injection’s Therapeutic Franchise
4 – NORD (National Organization for Rare Disorders). Cervical Dystonia (July 19, 2019) Retrieved from: https://rarediseases.org/rare-diseases/cervical-dystonia/. Accessed 9/29/20
5 – Marsh W, et al. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurology 2014
INDICATION
DAXXIFY™ (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DaxibotulinumtoxinA for Injection and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DaxibotulinumtoxinA for Injection is not approved for the treatment of spasticity or any conditions other than glabellar lines.
IMPORTANT SAFETY INFORMATION
Contraindications
DAXXIFY™ contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
The potency Units of DAXXIFY™ are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Drug Interactions
Co-administration of DAXXIFY™ and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY™ may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY™ is unknown.
Use in Specific Populations
DAXXIFY™ is not recommended for use in children or pregnant women.
Please see DAXXIFY™ full Prescribing Information, including Boxed Warning and Medication Guide.
